Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Lifshitz Law Firm Announces Investigation of Chemed Corporation, Overhill Farms, Inc., Theragenics Corporation, and Websense, Inc.

May 22, 2013

NEW YORK, May 22, 2013 /PRNewswire/ —

Chemed Corporation

Lifshitz Law Firm announces that it is investigating potential claims against the board of Chemed Corporation (“Chemed” or the “Company”) (CHE). On May 2, 2013, the government filed a False Claims Act complaint against the Company and certain of its hospice-related subsidiaries alleging that, since at least 2002, Vitas, and since 2004, the Company, submitted or caused the submission of false claims to the Medicare program by (a) billing Medicare for unnecessary crisis care services, and (b) admitting patients who were not eligible for the Medicare hospice benefit. The firm is investigating legal claims against the officers and Board of Directors of Chemed.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Overhill Farms, Inc.

Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Overhill Farms, Inc. (“Overhill Farms” or the “Company”) (OFI) to Bellisio Foods, Inc. in a cash transaction valued at approximately $80.9 million or $5.00 per share in cash.

Lifshitz Law Firm’s investigation is focused on whether the proposed deal provides adequate value to the Company’s shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Theragenics Corporation

Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the receipt of a proposal from Juniper Investment Company, LLC (“Juniper”) to acquire all of the Theragenics Corporation (“Theragenics” or the “Company”) (TGX) outstanding common stock for $2.25 to $2.30 per share in cash. The Company has entered into an agreement (“Letter Agreement”) dated May 12, 2013 to deal and negotiate exclusively with Juniper through June 11, 2013 regarding a merger transaction.

Lifshitz Law Firm’s investigation is focused on whether the Board of Directors of the Company is acting in the Company’s shareholders’ best interests in connection with the sale process.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Websense, Inc.

Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Websense, Inc. (“Websense” or the “Company”) (WBSN) to Vista Equity Partners for consideration of $24.75 in cash for each share of Websense common stock held by shareholders.

Lifshitz Law Firm’s investigation is focused on whether the proposed transaction provides adequate value to the Company’s shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at (212) 213-6222 Ext. 18 or by sending an e-mail including your contact information to: info@jlclasslaw.com.

Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm. The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41(st) Street, New York, New York 10017, (212) 213-6222. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law Firm
Phone: 212-213-6222
Email: info@jlclasslaw.com

SOURCE Lifshitz Law Firm


Source: PR Newswire